Eye-tracking-based assessment of cognitive function in low-resource settings.
Linda Forssman, Per Ashorn, Ulla Ashorn...
https://pubmed.ncbi.nlm.nih.gov/27551061/Actively Recruiting
Led by Sykehuset Innlandet HF · Updated on 2023-04-18
600
Participants Needed
1
Research Sites
208 weeks
Total Duration
Vitamin B12 deficiency is a common micronutrient shortage worldwide, including in places like Norway. Vitamin B12 is essential for healthy cell growth and brain development, especially in infants. This research investigates the effects of daily oral vitamin B12 supplements on infants brain development and growth. The study is a randomized, controlled trial enrolling breastfed infants to assess neurodevelopment, growth, and other health outcomes related to vitamin B12 status. Infants aged between 1 and 2 months will be screened for high plasma total homocysteine levels. Those with elevated levels will receive a 400 microgram dose of vitamin B12 cyanocobalamin via intramuscular injection. Infants without elevated levels will have their blood samples stored and analyzed after one year without receiving the supplement. Pregnant women are informed about the study early, and infants with confirmed deficiency receive treatment outside the randomized trial. Participants will be monitored with various assessments including neurodevelopmental evaluations at 12 months and later in childhood, growth measurements, and measures of nervous system function. Blood samples will be collected at 1 to 3 months and 12 months to check vitamin levels. Safety is tracked with reports of any adverse events three months after treatment. The study will last at least 12 months with ongoing follow-up to understand the impact of vitamin B12 supplementation on infant health.
CONDITIONS
Early Infant Micronutrition and Development
C
Carolien Konijnenberg, Ph.D
K
Kjersti S Bakken, Ph.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sykehuset Innlandet HF
Lead Sponsor
University of Bergen
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single administration at enrollment
Participants with elevated plasma total homocysteine concentrations receive an intramuscular injection of 400 µg cobalamin (vitamin B12).
1 treatment visit (in-person)
Duration - Up to 12 months with additional assessment at 5 years
Participants are monitored for neurodevelopment, vagal tone, eye tracking, and adverse events after treatment.
Multiple visits including assessments at 4-12 months, 12 months, and 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Linda Forssman, Per Ashorn, Ulla Ashorn...
https://pubmed.ncbi.nlm.nih.gov/27551061/Kjersti S Bakken, Ingrid Kvestad, Sol Maja Graasvold Bjørkevoll...
https://pubmed.ncbi.nlm.nih.gov/37080624/Daphna K Dror, Lindsay H Allen
https://pubmed.ncbi.nlm.nih.gov/18454811/Paulo Graziano, Karen Derefinko
https://pubmed.ncbi.nlm.nih.gov/23648264/Ingrid Kvestad, Sunita Taneja, Tivendra Kumar...
https://pubmed.ncbi.nlm.nih.gov/26098427/Sol Maja G Bjørkevoll, Maria O'Keeffe, Carolien Konijnenberg...
https://pubmed.ncbi.nlm.nih.gov/40609749/Tor A Strand, Sunita Taneja, Per M Ueland...
https://pubmed.ncbi.nlm.nih.gov/23283502/Ingrid Torsvik, Per Magne Ueland, Trond Markestad...
https://pubmed.ncbi.nlm.nih.gov/24025626/Anne-Lise Bjørke-Monsen
https://pubmed.ncbi.nlm.nih.gov/24845709/Gry Hay, Carole Johnston, Andrew Whitelaw...
https://pubmed.ncbi.nlm.nih.gov/18614730/Sykehuset Innlandet HF
Lead Sponsor
University of Bergen
Collaborating Sponsor